MX2014006015A - Derivados de 3-fenil-isoquinolin-1 (2h) -ona como inhibidores de parp-1. - Google Patents

Derivados de 3-fenil-isoquinolin-1 (2h) -ona como inhibidores de parp-1.

Info

Publication number
MX2014006015A
MX2014006015A MX2014006015A MX2014006015A MX2014006015A MX 2014006015 A MX2014006015 A MX 2014006015A MX 2014006015 A MX2014006015 A MX 2014006015A MX 2014006015 A MX2014006015 A MX 2014006015A MX 2014006015 A MX2014006015 A MX 2014006015A
Authority
MX
Mexico
Prior art keywords
compounds
isoquinolin
phenyl
derivatives
parp
Prior art date
Application number
MX2014006015A
Other languages
English (en)
Spanish (es)
Inventor
Mariano Enrico Papeo Gianluca
Cirla Alessandra
D Anello Matteo
Scolaro Alessandra
Zuccotto Fabio
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47227787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014006015(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of MX2014006015A publication Critical patent/MX2014006015A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014006015A 2011-11-25 2012-11-20 Derivados de 3-fenil-isoquinolin-1 (2h) -ona como inhibidores de parp-1. MX2014006015A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11190687 2011-11-25
EP12161489 2012-03-27
PCT/EP2012/073125 WO2013076090A1 (en) 2011-11-25 2012-11-20 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors

Publications (1)

Publication Number Publication Date
MX2014006015A true MX2014006015A (es) 2014-06-04

Family

ID=47227787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006015A MX2014006015A (es) 2011-11-25 2012-11-20 Derivados de 3-fenil-isoquinolin-1 (2h) -ona como inhibidores de parp-1.

Country Status (14)

Country Link
US (1) US9422243B2 (enExample)
EP (1) EP2788328B1 (enExample)
JP (1) JP6106182B2 (enExample)
KR (1) KR20140097457A (enExample)
CN (1) CN103946214B (enExample)
AU (1) AU2012342562B2 (enExample)
BR (1) BR112014012031A2 (enExample)
CA (1) CA2856759A1 (enExample)
CL (1) CL2014001323A1 (enExample)
EA (1) EA027800B1 (enExample)
ES (1) ES2676068T3 (enExample)
IN (1) IN2014CN04671A (enExample)
MX (1) MX2014006015A (enExample)
WO (1) WO2013076090A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
CA2922469A1 (en) 2013-09-11 2015-03-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
JP6663350B2 (ja) * 2014-01-16 2020-03-11 クロヴィス・オンコロジー,インコーポレーテッド ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのparp阻害剤の使用
JP6917989B2 (ja) 2015-11-06 2021-08-11 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 神経学的疾患を処置するためのムスカリン受容体4(m4)アンタゴニストとしての、n−[2−(1−ベンジルピペリジン−4−イル)エチル]−4−(ピラジン−2−イル)−ピペラジン−1−カルボキサミド誘導体および関連化合物
US12486250B2 (en) 2019-12-06 2025-12-02 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
KR20250023494A (ko) 2022-06-15 2025-02-18 아스트라제네카 아베 암 치료를 위한 병용 요법
JP2026515235A (ja) 2023-05-11 2026-05-14 アストラゼネカ・アクチエボラーグ 癌を治療するためのparp1阻害剤と選択的エストロゲン分解薬の併用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090334A1 (en) * 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
US20040176361A1 (en) * 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
AU2003255149A1 (en) * 2002-07-24 2004-02-09 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
WO2009104802A1 (en) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
TWI499418B (zh) * 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉-1(2h)-酮衍生物

Also Published As

Publication number Publication date
US9422243B2 (en) 2016-08-23
AU2012342562B2 (en) 2017-02-23
IN2014CN04671A (enExample) 2015-09-18
EP2788328A1 (en) 2014-10-15
HK1200166A1 (en) 2015-07-31
JP2014533709A (ja) 2014-12-15
CN103946214B (zh) 2016-08-17
CN103946214A (zh) 2014-07-23
EP2788328B1 (en) 2018-01-31
BR112014012031A2 (pt) 2017-05-30
WO2013076090A1 (en) 2013-05-30
EA027800B1 (ru) 2017-09-29
CA2856759A1 (en) 2013-05-30
US20140336192A1 (en) 2014-11-13
ES2676068T3 (es) 2018-07-16
JP6106182B2 (ja) 2017-03-29
AU2012342562A1 (en) 2014-07-10
KR20140097457A (ko) 2014-08-06
EA201491026A1 (ru) 2014-11-28
CL2014001323A1 (es) 2014-09-05

Similar Documents

Publication Publication Date Title
WO2011006794A8 (en) 3-oxo-2, 3-dihydro-1h-isoindole-4-carboxamides as parp inhibitors
MX367425B (es) Derivados de 4-carboxamido-isoindolinona como inhibidores selectivos de parp-1.
MX2014013090A (es) Derivados de pirrolotriazinona.
WO2013163190A8 (en) Dna-pk inhibitors
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
WO2014023390A3 (en) (aza-)isoquinolinone derivatives
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
MX356205B (es) Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
MY203474A (en) Substituted tricyclic compounds as fgfr inhibitors
MX365702B (es) Inhibidores de pirazolil quinoxalina cinasa.
WO2011006803A8 (en) 3-0x0-2, 3, -dihydro-1h-isoindole-4-carboxamides with selective parp-1 inhibition
TN2013000325A1 (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
NZ630170A (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
WO2010147898A3 (en) Small molecule inhibitors of spleen tyrosine kinase (syk)
WO2013192049A3 (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
MX2011009033A (es) Inhibidores triciclicos de cinasa pirazolopiridina.
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
EA201491026A1 (ru) Производные 3-фенилизохинолин-1(2h)-она в качестве ингибиторов parp-1
HK1205742A1 (en) 6- (4- (1 -amino- 3 -hydroxycyclobutyl) phenyl) - 5 - phenyl (furo, thieno or pyrrolo) [2, 3-d]pyrimidin- 4 - one derivatives for the treatment of cancer
MX364859B (es) Derivados de imidazopirazinona.
MX369393B (es) Derivados de ftalazina.
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase